glycoprotein IIb/IIIa inhibitor
Jump to navigation
Jump to search
Indications
- adjunctive agent with angioplasty (PCI)*
- may be useful for acute coronary syndrome, NSTEMI (not without PCI[2])*
* reserved for use at the time of PCI[2]
* when used in combination with PCI in CABG graft, may be associated with higher incidence of MI[1]
Contraindications
- use in association with thrombolytic therapy
Benefit/risk
- adjunctive agent with PCI for patients with STEMI[3]
- no mortality benefit
- number needed to harm: 116 for major hemorrhage[3]
Adverse effects
- drug adverse effects of antiplatelet agents
- drug adverse effects of glycoprotein IIb/IIIa inhibitor
- drug adverse effects of antithrombotic agent(s)
More general terms
More specific terms
Additional terms
References
- ↑ 1.0 1.1 Internal Medicine News, July 2005, pg 56
- ↑ 2.0 2.1 2.2 2.3 Medical Knowledge Self Assessment Program (MKSAP) 16, 19 American College of Physicians, Philadelphia 2012, 2022
- ↑ 3.0 3.1 3.2 The NNT: Glycoprotein Inhibitors given for Major Heart Attack (STEMI) Patients Receiving Stents or Angioplasty. http://www.thennt.com/nnt/glycoprotein-inhibitors-for-stemi/